No Data
Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Zhejiang Jolly Pharmaceutical (300181.SZ): Bailin tablets are proposed to be selected for the national Chinese Patent Medicine procurement alliance's centralized purchasing.
Zhejiang Jolly Pharmaceutical (300181.SZ) announced that recently, the company and its controlling subsidiary Qinghai Zhuofeng Cordyceps Sinensis Pharmaceutical...
Zhejiang Jolly Pharmaceutical (300181.SZ): Bailin capsules have officially been launched for sale.
On December 24, Gelonghui reported that Zhejiang Jolly Pharmaceutical (300181.SZ) announced on the investor interaction platform that the company’s Bailin capsules have officially launched for sale.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Seems To Use Debt Quite Sensibly
Jolly Pharmaceutical to Take Controlling Stake in Lingyi Biotech in Cooperation Deal; Shares Up 3%
Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
